Also known as: CARsgen
CARsgen Therapeutics is a biopharmaceutical company focused on developing innovative CAR T-cell therapies for hematologic malignancies, solid tumors, and autoimmune diseases. It operates as a Hong Kong-listed company with core research and development activities in China.
CAR T-cell therapy market advances with AI-driven manufacturing improvements and over 250 companies developing 500+ drug candidates, including breakthrough solid tumor treatments and GPC3-targeted therapies for hepatocellular carcinoma.
Three comprehensive reports examine the monoclonal antibody landscape, covering CD47-targeted immunotherapy pipelines, competitive analysis of 180+ companies developing mAb therapeutics, and recombinant antibody market forecasts through 2033.
